Search
Results: 26
Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
In many phase II trials in solid tumours, patients are assessed using endpoints based on the Response Evaluation Criteria in Solid Tumours (RECIST) scale. Often, analyses are based on the response rate. This is the proportion of...
continuous tumour shrinkage endpoints longitudinal model phase II cancer trial Clinical Trials Phase II as Topic Colonic Neoplasms Computer Simulation Disease Progression Endpoint Determination Humans Logistic Models Medical Oncology Neoplasms Randomized Controlled Trials as Topic Research Design Treatment Outcome
Active surveillance of prostate cancer
BACKGROUND: Active surveillance is considered a mainstream strategy in the management of patients with low-risk prostate cancer. A mission-critical step in implementing a robust active surveillance program and plan its resource...
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Stefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, Bernard Escudier, Stefanie Fischer, James Larkin, Viktor Gruenwald, David McDermott, Jan Oldenburg, Aurelius Omlin, Camillo Porta, Brian Rini, Manuela Schmidinger, Cora Sternberg, Christian Rothermundt
Sep 15, 2020
BACKGROUND: The coronavirus pandemic has provoked discussions among healthcare providers how to manage cancer patients when faced with the threat of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) infection....
covid-19 decision criteria pandemic renal cell carcinoma treatment pattern Antineoplastic Agents Betacoronavirus covid-19 Carcinoma Renal Cell Clinical Decision-Making Coronavirus Infections Humans Immunologic Factors Kidney Neoplasms Medical Oncology Pandemics Pneumonia Viral Practice Patterns Physicians' Protein Kinase Inhibitors SARS-CoV-2 Urology
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology.
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Adria Lopez-Fernandez, Markus Jonsson, Ali Razzak, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Richard D Baird, Yohann Loriot, Christophe Massard, Patricia Martin-Romano, Frans Opdam, Richard F Schlenk, Claudio Vernieri, Michele Masucci, Xenia Villalobos, Elena Chavarria, Cancer Core Europe consortium, Judith Balmaña, Giovanni Apolone, Carlos Caldas, Jonas Bergh, Ingemar Ernberg, Stefan Fröhling, Elena Garralda, Claes Karlsson, Josep Tabernero, Emile Voest, Jordi Rodon, Janne Lehtiö
Feb 28, 2022
There is a growing need for systems that efficiently support the work of medical teams at the precision-oncology point of care. Here, we present the implementation of the Molecular Tumor Board Portal (MTBP), an academic clinical...
ECCO Essential Requirements for Quality Cancer Care
Ian Banks, David Weller, Mehmet Ungan, Peter Selby, Matti Aapro, Marc Beishon, Marije Bolt, Fiona Bonanno, Claire Champeix, Csaba Dégi, Lisa Jelf Eneqvist, Joanna Kazmierska, Agnieszka Kolacinska, Simon Malas, Sébastien Moine, Danica Rotar Pavlic, Richard Price, Fiona Walter, Lynda Wyld
Sep 05, 2019
ECCO Essential Requirements for Quality Cancer Care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to cancer patients. They are written by European experts...
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients.
Richard Baird, Ian Banks, David Cameron, John Chester, Helena Earl, Mark Flannagan, Adam Januszewski, Richard Kennedy, Sarah Payne, Emlyn Samuel, Hannah Taylor, Roshan Agarwal, Samreen Ahmed, Caroline Archer, Ruth Board, Judith Carser, Ellen Copson, David Cunningham, Rob Coleman, Adam Dangoor, Graham Dark, Diana Eccles, Chris Gallagher, Adam Glaser, Richard Griffiths, Geoff Hall, Marcia Hall, Danielle Harari, Michael Hawkins, Mark Hill, Peter Johnson, Alison Jones, Tania Kalsi, Eleni Karapanagiotou, Zoe Kemp, Janine Mansi, Ernie Marshall, Alex Mitchell, Maung Moe, Caroline Michie, Richard Neal, Tom Newsom-Davis, Alison Norton, Richard Osborne, Gargi Patel, John Radford, Alistair Ring, Emily Shaw, Rod Skinner, Dan Stark, Sam Turnbull, Galina Velikova, Jeff White, Alison Young, Johnathan Joffe, Peter Selby
Jan 13, 2016
Boosting care and knowledge about hereditary cancer
Janet R Vos, Lisette Giepmans, Claas Röhl, Nicoline Geverink, Nicoline Hoogerbrugge, ERN GENTURIS
Feb 07, 2020
Approximately 27-36 million patients in Europe have one of the ~ 5.000-8.000 known rare diseases. These patients often do not receive the care they need or they have a substantial delay from diagnosis to treatment. In March...
Cross border health care European Reference Network Genetic Hereditary cancer Rare Diseases Syndrome Clinical Competence Databases Factual Europe Genetic Predisposition to Disease Genetic Testing Humans Information Dissemination Information Services International Cooperation Medical Oncology Neoplastic Syndromes Hereditary Quality Improvement Rare Diseases Registries Remote Consultation Time-to-Treatment
UK quantitative WB-DWI technical workgroup
Anna Barnes, Roberto Alonzi, Matthew Blackledge, Geoff Charles-Edwards, David J Collins, Gary Cook, Glynn Coutts, Vicky Goh, Martin Graves, Charles Kelly, Dow-Mu Koh, Hazel McCallum, Marc E Miquel, James O'Connor, Anwar Padhani, Rachel Pearson, Andrew Priest, Andrea Rockall, James Stirling, Stuart Taylor, Nina Tunariu, Jan van der Meulen, Darren Walls, Jessica Winfield, Shonit Punwani
Aug 29, 2018
OBJECTIVE: Application of whole body diffusion-weighted MRI (WB-DWI) for oncology are rapidly increasing within both research and routine clinical domains. However, WB-DWI as a quantitative imaging biomarker (QIB) has...
The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers
Jonathan Shamash, Wendy Ansell, Constantine Alifrangis, Benjamin Thomas, Peter Wilson, Sara Stoneham, Danish Mazhar, Anne Warren, Tristan Barrett, Susanna Alexander, Sarah Rudman, Michelle Lockley, Daniel Berney, Anju Sahdev
Oct 05, 2020
BACKGROUND: The germ cell supranetwork multidisciplinary team (SMDT) for the Anglian Network covers a population of 7.5 million. METHODS: We reviewed 10 years of SMDT discussion and categorised them into five domains ((1)...
Biological material collection to advance translational research and treatment of children with CNS tumours
Stefan Rutkowski, Piergiorgio Modena, Daniel Williamson, Kornelius Kerl, Karsten Nysom, Barry Pizer, Ute Bartels, Stephanie Puget, François Doz, Antony Michalski, Katja von Hoff, Mathilde Chevignard, Shivaram Avula, Matthew J Murray, Stefan Schönberger, Thomas Czech, Antoinette YN Schouten-van Meeteren, Uwe Kordes, Christof M Kramm, Dannis G van Vuurden, Esther Hulleman, Geert O Janssens, Guirish A Solanki, Marie-Luise C van Veelen, Ulrich Thomale, Martin U Schuhmann, Chris Jones, Felice Giangaspero, Dominique Figarella-Branger, Torsten Pietsch, Steve C Clifford, Stefan M Pfister, Stefaan W Van Gool
Feb 15, 2019
Paediatric CNS tumours are the most common cause of childhood cancer-related morbidity and mortality, and improvements in their diagnosis and treatment are needed. New genetic and epigenetic information about paediatric CNS...
Analysing the attributes of Comprehensive Cancer Centres and Cancer Centres across Europe to identify key hallmarks.
Sebastian Kehrloesser, Simon Oberst, Willien Westerhuis, Astrid Wendler, Anke Wind, Harriët Blaauwgeers, Jean-Benoit Burrion, Péter Nagy, Gunnar Saeter, Eva Gustafsson, Paolo De Paoli, József Lovey, Claudio Lombardo, Thierry Philip, Dominique de Valeriola, Marjet Docter, Femke Boomsma, Mahasti Saghatchian, Marek Svoboda, Irene Philip, Francesco Monetti, Henk Hummel, Gordon McVie, Renée Otter, Wim van Harten
May 05, 2021
There is a persistent variation in cancer outcomes among and within European countries suggesting (among other causes) inequalities in access to or delivery of high-quality cancer care. European policy (EU Cancer Mission and...
accreditation Clinical Trials comprehensive cancer center multidisciplinarity quality standard Translational Research Academies and Institutes Biomedical Research Cancer Care Facilities Cohort Studies Europe Humans Medical Oncology Neoplasms Patient Care Team Patient-Centered Care Quality of Health Care Translational Research Biomedical
Recent Advancements and Applications of Human Immune System Mice in Preclinical Immuno-Oncology.
Michelle Curran, Maelle Mairesse, Alba Matas-Céspedes, Bethany Bareham, Giovanni Pellegrini, Ardi Liaunardy, Edward Powell, Rebecca Sargeant, Emanuela Cuomo, Richard Stebbings, Catherine J Betts, Kourosh Saeb-Parsy
Jan 20, 2020
Significant advances in immunotherapies have resulted in the increasing need of predictive preclinical models to improve immunotherapeutic drug development, treatment combination, and to prevent or minimize toxicity in clinical...
Accelerating drug development for neuroblastoma
Lucas Moreno, Giuseppe Barone, Steven G DuBois, Jan Molenaar, Matthias Fischer, Johannes Schulte, Angelika Eggert, Gudrun Schleiermacher, Frank Speleman, Louis Chesler, Birgit Geoerger, Michael D Hogarty, Meredith S Irwin, Nick Bird, Guy B Blanchard, Sean Buckland, Hubert Caron, Susan Davis, Bram De Wilde, Hedwig E Deubzer, Emmy Dolman, Martin Eilers, Rani E George, Sally George, Štěrba Jaroslav, John M Maris, Lynley Marshall, Melinda Merchant, Peter Mortimer, Cormac Owens, Anna Philpott, Evon Poon, Jerry W Shay, Roberto Tonelli, Dominique Valteau-Couanet, Gilles Vassal, Julie R Park, Andrew DJ Pearson
Jul 29, 2020
Only one class of targeted agents (anti-GD2 antibodies) has been incorporated into front-line therapy for neuroblastoma since the 1980s. The Neuroblastoma New Drug Development Strategy (NDDS) initiative commenced in 2012 to...
Clinical Trials Drug development epigenetics MYCN Neuroblastoma phase I Preclinical testing Antineoplastic Agents Brain Neoplasms Child Congresses as Topic Drug development Drug Discovery Europe Humans Medical Oncology Molecular Targeted Therapy Neuroblastoma Pediatrics Protein Kinase Inhibitors therapies Investigational
Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma
JM Kalish, L Doros, LJ Helman, RC Hennekam, RP Kuiper, SM Maas, ER Maher, KE Nichols, SE Plon, CC Porter, S Rednam, KAP Schultz, LJ States, GE Tomlinson, K Zelley, TE Druley
Aug 09, 2017
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
Inge MM Lakeman, Mar DM Rodríguez-Girondo, Andrew Lee, Nandi Celosse, Merel E Braspenning, Klaartje van Engelen, Irma van de Beek, Annemiek H van der Hout, Encarna B Gómez García, Arjen R Mensenkamp, Margreet Gem Ausems, Maartje J Hooning, Muriel A Adank, Antoinette Hollestelle, Marjanka K Schmidt, Christi J van Asperen, Peter Devilee
Sep 27, 2022
Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.
Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William PD Hendricks, David G Huntsman, Jessica D Lang, Krystal A Orlando, Amit M Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M Trent, Michael Witcher, Leora Witkowski, W Glenn McCluggage, Douglas A Levine, William D Foulkes, Bernard E Weissman
Feb 18, 2020
Antineoplastic Combined Chemotherapy Protocols Carcinoma Small Cell Chemotherapy Adjuvant Chromatin Assembly and Disassembly DNA Helicases Female gynecology Humans hypercalcemia Medical Oncology Mutation Nuclear Proteins Ovarian Neoplasms Ovariectomy Ovary Practice Guidelines as Topic Radiotherapy Adjuvant Stem Cell Transplantation Survival Rate Transcription Factors Treatment Outcome
Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Helen Mossop, Michael J Grayling, Ferdia A Gallagher, Sarah J Welsh, Grant D Stewart, James MS Wason
Jan 28, 2022
Support systems to guide clinical decision-making in precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, Jorrit Boekel, Richard Baird, Irene Braña, Luigi De Petris, Jeffrey Yachnin, Christophe Massard, Frans L Opdam, Richard Schlenk, Claudio Vernieri, Elena Garralda, Michele Masucci, Xenia Villalobos, Elena Chavarria, Cancer Core Europe consortium, Fabien Calvo, Stefan Fröhling, Alexander Eggermont, Giovanni Apolone, Emile E Voest, Carlos Caldas, Josep Tabernero, Ingemar Ernberg, Jordi Rodon, Janne Lehtiö
Jul 08, 2020
To the editor: the optimal management of cancer patients is increasingly dependent on individualized treatments guided by tumor sequencing data. As comprehensive genomic tests become routine in many disease settings and academic...
Targeted sequencing in DLBCL, molecular subtypes, and outcomes
Stuart E Lacy, Sharon L Barrans, Philip A Beer, Daniel Painter, Alexandra G Smith, Eve Roman, Susanna L Cooke, Camilo Ruiz, Paul Glover, Suzan JL Van Hoppe, Nichola Webster, Peter J Campbell, Reuben M Tooze, Russell Patmore, Cathy Burton, Simon Crouch, Daniel J Hodson
Feb 18, 2020
Adolescent Adult Aged Aged 80 and over Biomedical Research Child Child Preschool Cohort Studies Community Networks DNA Mutational Analysis Female Gene Expression Profiling Gene Expression Regulation Neoplastic Hematologic Neoplasms Humans Infant Lymphoma Large B-Cell Diffuse Male Medical Oncology Middle Aged Molecular Diagnostic Techniques Neoplasm Staging Prognosis Transcriptome United Kingdom Exome Sequencing Young Adult
Reply to 'Assembling the brain trust
Kenneth Aldape, Kevin M Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R Gilbert, Nicholas Gottardo, David H Gutmann, Darren Hargrave, Eric C Holland, David TW Jones, Johanna A Joyce, Pamela Kearns, Mark W Kieran, Ingo K Mellinghoff, Melinda Merchant, Stefan M Pfister, Steven M Pollard, Vijay Ramaswamy, Jeremy N Rich, Giles W Robinson, David H Rowitch, John H Sampson, Michael D Taylor, Paul Workman, Richard J Gilbertson
Sep 27, 2019
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and...
A latent variable model for improving inference in trials assessing the effect of dose on toxicity and composite efficacy endpoints.
It is often of interest to explore how dose affects the toxicity and efficacy properties of a novel treatment. In oncology, efficacy is often assessed through response, which is defined by a patient having no new tumour lesions...
Major milestones in translational oncology.
Tommaso A Dragani, Antoni Castells, Vathany Kulasingam, Eleftherios P Diamandis, Helena Earl, Wade T Iams, Christine M Lovly, JP Michiel Sedelaar, Jack A Schalken
Sep 29, 2016
Translational oncology represents a bridge between basic research and clinical practice in cancer medicine. Today, translational research in oncology benefits from an abundance of knowledge resulting from genome-scale studies...
Biomarkers Breast Cancer vaccines Colorectal Early Diagnosis Genetic profile Immunotherapy Individual risk Liquid biopsy Lung Mutational landscape Next generation sequencing Ovarian Prostate Tumorigenesis Biomarkers Tumor Humans Medical Oncology Molecular Targeted Therapy Translational Research Biomedical
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
Inge MM Lakeman, Mar DM Rodríguez-Girondo, Andrew Lee, Nandi Celosse, Merel E Braspenning, Klaartje van Engelen, Irma van de Beek, Annemiek H van der Hout, Encarna B Gómez García, Arjen R Mensenkamp, Margreet Gem Ausems, Maartje J Hooning, Muriel A Adank, Antoinette Hollestelle, Marjanka K Schmidt, Christi J van Asperen, Peter Devilee
Oct 26, 2022
Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology.
|
|< |
< |
1 |